Global Blood Therapeutics acquisition to boost Pfizer’s sickle cell pipeline
In a $5.4 billion deal that will boost its rare disease treatment business, Pfizer is buying the pioneer in treatments for sickle cell disease, […]
Global Blood Therapeutics acquisition to boost Pfizer’s sickle cell pipeline Read More »